Assembly Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASMB research report →
Range $50 – $53
Price Chart
About the company
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV.
- CEO
- Jason A. Okazaki
- IPO
- 2010
- Employees
- 73
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on ASMB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $445.19M
- P/E
- 40.82
- PEG
- 0.06
- P/S
- 5.94
- P/B
- 1.38
- EV/EBITDA
- 6102.37
- Div Yield
- 0.00%
- Gross Margin
- 77.73%
- Op Margin
- -11.75%
- Net Margin
- -0.06%
- ROE
- -0.02%
- ROIC
- -2.86%
Latest fiscal year · YoY change
- Revenue
- $72.30M+153.5%
- Gross Profit
- $72.17M+363.3%
- Op Income
- $-12,118,000
- Net Income
- $-6,122,000+84.8%
- EPS
- $-0.55+91.8%
- OCF Growth
- +19.6%
- FCF Growth
- +19.5%
- 52W High
- $39.71
- 52W Low
- $21.80
- 50D MA
- $28.81
- 200D MA
- $28.31
- Beta
- 1.13
- RSI (14)
- 26
- Avg Volume
- 274.54K
No earnings-call transcripts are available for ASMB yet.
- Free Float
- 62.9%
- Shares Outstanding
- 19.82M
- Float Shares
- 12.47M
of shares held by institutions
74 13F filers
Buy/sell ratio 7.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ASMB, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gilead Sciences, Inc. | 4.98M | ▲ 471.70K |
| Farallon Capital Management LLC | 1.60M | ▲ 377.00K |
| Paradigm Biocapital Advisors LP | 1.55M | ▲ 888.50K |
| Commodore Capital LP | 1.42M | ▲ 415.00K |
| Ra Capital Management, L.P. | 1.02M | 0 |
| Jupiter Topco LLC | 849.31K | ▲ 849.31K |
| Janus Henderson Group Ltd. | 849.31K | ▲ 11.38K |
| Blackrock, Inc. | 766.82K | ▲ 564.08K |
| Parkman Healthcare Partners LLC | 721.18K | ▲ 309.95K |
| Vanguard Group Inc | 572.90K | ▲ 70.79K |
| Vanguard Capital Management LLC | 558.94K | ▲ 68.50K |
| Point72 Asset Management, L.P. | 460.59K | ▲ 116.49K |
Held by 99 ETFs
Biggest fund positions in ASMB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Bjorkquist Jeanette M | sell | 29 |
| Mar 29, 26 | Gaggar Anuj | other | 14,000 |
| Mar 29, 26 | White Nicole S | other | 14,000 |
| Jun 4, 26 | McHutchison John G | other | 8,000 |
| Jun 4, 26 | Mahony Susan | other | 8,000 |
| Jun 4, 26 | Johnson-Pratt Lisa | other | 8,000 |
| Jun 4, 26 | Houghton Michael | other | 8,000 |
| Jun 4, 26 | Consylman Gina | other | 8,000 |
| Jun 4, 26 | ALTIG ANTHONY E | other | 8,000 |
| Mar 29, 26 | Bjorkquist Jeanette M | other | 3,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ASMB coverage
Recent articles, reports, and earnings notes.
No research on ASMB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASMB report →Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB)
defenseworld.net · Oct 6
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
globenewswire.com · Oct 5
Best Momentum Stocks to Buy for September 17th
zacks.com · Sep 17
New Strong Buy Stocks for September 17th
zacks.com · Sep 17
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
globenewswire.com · Sep 10
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
zacks.com · Sep 9
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
globenewswire.com · Sep 8
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
zacks.com · Sep 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.